This paper is in the following e-collection/theme issue:

Addiction Medicine (19) Substance Abuse (379) Gastroenterology and Hepatology (51)

Published on in Vol 7, No 2 (2018): Jul-Dec

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/10313, first published .
Hepatitis C Prevalence and Management Among Patients Receiving Opioid Substitution Treatment in General Practice in Ireland: Baseline Data from a Feasibility Study

Hepatitis C Prevalence and Management Among Patients Receiving Opioid Substitution Treatment in General Practice in Ireland: Baseline Data from a Feasibility Study

Hepatitis C Prevalence and Management Among Patients Receiving Opioid Substitution Treatment in General Practice in Ireland: Baseline Data from a Feasibility Study

Authors of this article:

Ross Murtagh1 Author Orcid Image ;   Davina Swan1 Author Orcid Image ;   Eileen O'Connor1 Author Orcid Image ;   Geoff McCombe1 Author Orcid Image ;   John S. Lambert1, 2 Author Orcid Image ;   Gordana Avramovic1, 2 Author Orcid Image ;   Walter Cullen1 Author Orcid Image
Article Authors Cited by (7) Tweetations (1) Metrics

Journals

  1. Lee S, Crofts N, Hung C. Macro-efforts for the micro-elimination of hepatitis C targeting people who inject drugs. International Journal of Infectious Diseases 2019;85:141 View
  2. Nic An Riogh E, Swan D, McCombe G, O’Connor E, Avramovic G, Macías J, Oprea C, Story A, Surey J, Vickerman P, Ward Z, Lambert J, Tinago W, Ianache I, Iglesias M, Cullen W. Integrating hepatitis C care for at-risk groups (HepLink): baseline data from a multicentre feasibility study in primary and community care. Journal of Antimicrobial Chemotherapy 2019;74(Supplement_5):v31 View
  3. Jessop A, Bass S, Brajuha J, Alhajji M, Burke M, Gashat M, Wellington C, Ventriglia N, Coleman J, D'Avanzo P. “Take Charge, Get Cured”: Pilot testing a targeted mHealth treatment decision support tool for methadone patients with hepatitis C virus for acceptability and promise of efficacy. Journal of Substance Abuse Treatment 2020;109:23 View
  4. Makarenko I, Artenie A, Hoj S, Minoyan N, Jacka B, Zang G, Barlett G, Jutras-Aswad D, Martel-Laferriere V, Bruneau J. Transitioning from interferon-based to direct antiviral treatment options: A potential shift in barriers and facilitators of treatment initiation among people who use drugs?. International Journal of Drug Policy 2019;72:69 View
  5. Bregenzer A, Krismer C, Wendel S, Roser P, Fux C. HCV elimination in a Swiss opioid agonist therapy programme – a cohort study. Swiss Medical Weekly 2022;152(4950):40009 View
  6. McCombe G, Swan D, Lambert J, O’Connor E, Ward Z, Vickerman P, Avramovic G, Crowley D, Tinago W, Mafirakureva N, Cullen W. Integrating Hepatitis C Care for Opioid Substitution Treatment Patients Attending General Practice: Feasibility, Clinical, and Cost-Effectiveness Analysis. Interactive Journal of Medical Research 2022;11(2):e35300 View
  7. Tandan M, Dunlea S, Bury G. Hepatitis C Infection and Treatment among Injecting Drug Users Attending General Practice: A Systematic Review and Meta-Analysis. International Journal of Environmental Research and Public Health 2023;20(8):5569 View